Premium Tyrosine Kinase Inhibitor (TKI) for Advanced Cancer Therapy | WHO-GMP Export Supply

🌍 Global Oncology Demand | Trusted Cancer Therapy Molecule

Sunitinib Malate Capsules are a widely recognized targeted anti-cancer therapy used in modern oncology protocols for managing advanced and metastatic cancers. As a multi-targeted tyrosine kinase inhibitor (TKI), it plays a key role in inhibiting tumor growth pathways and angiogenesis.

This product is actively demanded across regulated and semi-regulated pharmaceutical markets including:
United States, Germany, United Kingdom, United Arab Emirates (UAE), Brazil, and South Africa.

💊 Product Snapshot

• Product Name: Sunitinib Malate Capsules
• Strengths: 12.5 mg / 25 mg / 50 mg
• Dosage Form: Oral Hard Gelatin Capsules
• Therapeutic Category: Anti-Cancer / Oncology / Targeted Therapy
• Drug Class: Tyrosine Kinase Inhibitor (TKI)
• Route: Oral Administration
• Rx Status: Prescription Only Medicine

🎯 Key Therapeutic Applications

Sunitinib Malate is clinically utilized in oncology protocols for:

• Metastatic Renal Cell Carcinoma (mRCC)
• Gastrointestinal Stromal Tumor (GIST) – after resistance/intolerance to imatinib
• Pancreatic Neuroendocrine Tumors (pNET)
• Post-surgical high-risk RCC adjuvant therapy

🧬 Mechanism of Action – Targeted Oncology Innovation

Sunitinib Malate delivers multi-pathway cancer control by inhibiting:

• VEGFR (tumor blood vessel formation blockade)
• PDGFR (tumor cell growth signaling inhibition)
• KIT, FLT3, RET receptor pathways

Clinical Advantage:

✔ Blocks tumor angiogenesis
✔ Slows cancer progression
✔ Helps control metastatic disease spread
✔ Supports precision oncology treatment strategies

📦 Available Strengths & Clinical Flexibility

Common Treatment Cycle:

50 mg once daily for 4 weeks → 2 weeks rest cycle

🌐 High-Demand Export Markets

🇺🇸 United States

• Growing demand for affordable oncology generics
• Widely used in RCC and GIST treatment protocols

🇩🇪 Germany & 🇬🇧 United Kingdom

• Strong adoption in EU oncology guidelines
• Preference for WHO-GMP certified generics

🇦🇪 United Arab Emirates

• Rapidly expanding oncology infrastructure
• High dependency on imported cancer drugs

🇧🇷 Brazil

• Public healthcare oncology procurement programs
• Rising demand for cost-effective targeted therapies

🇿🇦 South Africa

• High oncology burden driving TKI demand
• Government and hospital tender procurement channels

⚙️ Why Global Buyers Choose Sunitinib Malate Capsules

✔ Multi-targeted anti-cancer therapy
✔ Clinically established oncology molecule
✔ Available in multiple strengths for precision dosing
✔ Suitable for hospital & institutional supply
✔ Strong global regulatory acceptance (FDA / EMA aligned markets)
✔ High demand in oncology procurement tenders

📦 Packaging & Quality Standards

• Export-grade blister / bottle packaging
• Manufactured under WHO-GMP certified facilities
• Stability-tested formulations
• Complete regulatory documentation support:
  • Certificate of Analysis (COA)
  • Material Safety Data Sheet (MSDS)
  • Batch traceability records
  • GMP compliance documents

🤝 Ideal For

• Oncology hospitals & cancer institutes
• International pharmaceutical distributors
• Government health procurement agencies
• Oncology tender suppliers
• Global wholesale pharma importers

🚀 Global Business Opportunity

The demand for Sunitinib Malate Capsules continues to grow due to increasing incidence of kidney cancer, GIST, and neuroendocrine tumors worldwide. This makes it a high-value oncology export product in regulated and semi-regulated markets.

📩 Business Inquiry / Export Orders

🌍 Export Coverage: USA | Germany | UK | UAE | Brazil | South Africa

📧 Email: info@cordiumpharma.com
📱 WhatsApp: +91-9405117673

⚠️ Regulatory Disclaimer

This product is intended for licensed pharmaceutical wholesalers, hospitals, and institutional buyers only. All imports must comply with local regulatory authority guidelines.